{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["37(1)"],"submitter":["Silpa-Archa S"],"pubmed_abstract":["<h4>Purpose</h4>To determine the sensitivity and specificity of syphilis antibody tests in vitreous samples and to propose an algorithm using vitreous syphilis antibody as a supplementary test to confirm syphilitic uveitis (SU).<h4>Methods</h4>A prospective case-control study was conducted at the Retina and Uveitis Clinic from May 2017 to January 2020. Initially, patients were classified based on syphilis serology into group 1 (positive testing) and group 2 (negative testing). Group 1 was further divided into 2 subgroups (group 1A and 1B) depending on their relevant clinical manifestations and clinical improvement. Group 2 served as a control group.<h4>Results</h4>Thirty-eight patients were enrolled in the study: 14 in group 1A, 5 in group 1B, and 19 in group 2B. No patient was assigned to"],"journal":["Eye (London, England)"],"pagination":["146-154"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9829903"],"repository":["biostudies-literature"],"pubmed_title":["Appraisal of vitreous syphilis antibody as a novel biomarker for the diagnosis of syphilitic uveitis: a prospective case-control study."],"pmcid":["PMC9829903"],"pubmed_authors":["Silpa-Archa S","Foster CS","Hoopholerb T"],"additional_accession":[]},"is_claimable":false,"name":"Appraisal of vitreous syphilis antibody as a novel biomarker for the diagnosis of syphilitic uveitis: a prospective case-control study.","description":"<h4>Purpose</h4>To determine the sensitivity and specificity of syphilis antibody tests in vitreous samples and to propose an algorithm using vitreous syphilis antibody as a supplementary test to confirm syphilitic uveitis (SU).<h4>Methods</h4>A prospective case-control study was conducted at the Retina and Uveitis Clinic from May 2017 to January 2020. Initially, patients were classified based on syphilis serology into group 1 (positive testing) and group 2 (negative testing). Group 1 was further divided into 2 subgroups (group 1A and 1B) depending on their relevant clinical manifestations and clinical improvement. Group 2 served as a control group.<h4>Results</h4>Thirty-eight patients were enrolled in the study: 14 in group 1A, 5 in group 1B, and 19 in group 2B. No patient was assigned to","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-04T14:12:59.179Z","creation":"2025-04-04T14:12:59.179Z"},"accession":"S-EPMC9829903","cross_references":{"pubmed":["35034091"],"doi":["10.1038/s41433-021-01902-6"]}}